INVA - Innoviva, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.64
-0.22 (-1.23%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close17.86
Open17.87
Bid15.79 x 200
Ask19.90 x 300
Day's range17.50 - 18.11
52-week range13.06 - 18.60
Volume846,062
Avg. volume1,055,585
Market cap1.782B
Beta (3Y monthly)0.77
PE ratio (TTM)10.37
EPS (TTM)1.70
Earnings date6 Feb 2019 - 11 Feb 2019
Forward dividend & yieldN/A (N/A)
Ex-dividend date2015-09-08
1y target est15.50
Trade prices are not sourced from all markets
  • 3 Reasons Momentum Stock Investors Will Love Innoviva (INVA)
    Zacks4 days ago

    3 Reasons Momentum Stock Investors Will Love Innoviva (INVA)

    Innoviva (INVA) stock is looking quite impressive for momentum-oriented investors as it has favorable price performance and is also seeing positive estimate revisions.

  • Stocks Trim Losses As Consumer Stocks Rise At Start Of Holiday Shopping Season
    Investor's Business Daily17 days ago

    Stocks Trim Losses As Consumer Stocks Rise At Start Of Holiday Shopping Season

    Stocks pared losses as the market started the final hour of a shortened session Friday, while some consumer stocks led at the start of the holiday shopping season.

  • IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses
    Investor's Business Daily20 days ago

    IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses

    Innoviva is the IBD Stock Of The Day as the biotech stock flirts with a breakout amid new uses for its GlaxoSmithKline-partnered medicines. Innoviva has several royalty deals with Glaxo.

  • Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe
    Zacks27 days ago

    Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe

    Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.

  • Moving Average Crossover Alert: Innoviva (INVA)
    Zackslast month

    Moving Average Crossover Alert: Innoviva (INVA)

    Innoviva, Inc. (INVA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front

  • Business Wirelast month

    Once-daily Trelegy Ellipta gains expanded COPD indication in Europe

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). While bronchodilation is recognised as the foundation of COPD therapy, many patients may continue to struggle with symptoms and exacerbations over time.

  • GlobeNewswirelast month

    Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Investor's Business Dailylast month

    IBD 50 Stocks To Watch: This Stock Rallied Despite A Miss On Earnings And Revenue

    The stock market's reaction was interesting for a company that just missed on earnings and revenue.

  • Associated Presslast month

    Innoviva: 3Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had profit of 43 cents. The biopharmaceutical company posted revenue of $61.7 million in the period. Innoviva shares have dropped 1 ...

  • Business Wirelast month

    Innoviva Reports Third Quarter 2018 Financial Results

    BRISBANE, Calif.-- -- Total net revenue rose 26.8% to $61.7 million compared with the third quarter of 2017. Net income attributable to Innoviva stockholders increased 98.1% from the third quarter of 2017 to $47.1 million, or $0.43 per diluted share. The Company made a partial repayment of $110.0 million on its Term B loan. Innoviva, Inc. today reported financial results for the third quarter ended ...

  • Business Wire3 months ago

    Trelegy Ellipta Receives Positive CHMP Opinion Supporting Expanded COPD Indication in Europe

    GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion today supporting the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/ vilanterol ‘FF/UMEC/VI’) in a broader group of patients with moderate to severe chronic obstructive pulmonary disease (COPD) and that labelling, if approved, will be updated to further reflect its effect on exacerbations of COPD. It would also reference the effect on exacerbations based on data from the InforMing the PAthway of COPD Treatment (IMPACT) study. Dr. Hal Barron, Chief Scientific Officer and President, R&D, GSK, said, “Many patients with COPD continue to experience exacerbations despite taking dual bronchodilator therapies.

  • What Does Nektar Therapeutics’ Valuation Trend Indicate?
    Market Realist4 months ago

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 

  • Analysts Remain Bullish on Nektar Stock in August
    Market Realist4 months ago

    Analysts Remain Bullish on Nektar Stock in August

    Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.

  • Business Wire5 months ago

    Innoviva Reports Second Quarter 2018 Financial Results

    BRISBANE, Calif.-- -- Total net revenue rose 14.6% to $67.1 million compared with the second quarter of 2017. Net income attributable to Innoviva stockholders increased 55.4% from the second quarter of 2017 to $54.6 million, or $0.49 per diluted share. The Company intends to prepay $110 million of its Term B Loan. Innoviva, Inc. today reported financial results for the second quarter ended June 30, ...

  • Innoviva And Other Great Growth Stocks
    Simply Wall St.5 months ago

    Innoviva And Other Great Growth Stocks

    Analysts are bullish on these following companies: Innoviva, Jazz Pharmaceuticals, Cardlytics. These companies are relatively strong financially, and have a great outlook in terms of profits and cash flow. AnalysingRead More...

  • 3 Top Healthcare Stocks to Buy in June
    Motley Fool6 months ago

    3 Top Healthcare Stocks to Buy in June

    These three mid-cap healthcare stocks could be your prescription for profits.

  • The Cheapest Drug Stocks to Buy Right Now
    Motley Fool6 months ago

    The Cheapest Drug Stocks to Buy Right Now

    All three of these bargains have forward P/E ratios of less than eight.

  • Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan
    Zacks6 months ago

    Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

    Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.

  • Business Wire6 months ago

    GSK Submits Regulatory Application in Japan for Once-Daily Single Inhaler Triple Therapy FF/UMEC/VI for Patients with COPD

    GlaxoSmithKline plc and Innoviva, Inc. today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for once-daily fluticasone furoate/umeclidinium/vilanterol under the proposed brand name of Trelegy Ellipta for the treatment of adults with chronic obstructive pulmonary disease .

  • Business Wire7 months ago

    Innoviva Names Geoffrey Hulme as Interim Principal Executive Officer

    Innoviva, Inc. (INVA) (“Innoviva”) today announced the appointment of Geoffrey Hulme as interim Principal Executive Officer effective May 21, 2018. Mr. Hulme has a 25 year career in finance and investment management with a record of creating and maximizing shareholder value. Prior to joining Innoviva, Mr. Hulme served as the owner and manager of Steel Valley Capital LLC and Steel Valley Advisors LLC, a Registered Investment Adviser.

  • Associated Press7 months ago

    Innoviva: 1Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had net income of 27 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 35 cents per share. The biopharmaceutical ...

  • Business Wire7 months ago

    Innoviva Reports First Quarter 2018 Financial Results

    Innoviva, Inc. today reported financial results for the first quarter ended March 31, 2018.